854 related articles for article (PubMed ID: 15709168)
1. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
2. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer.
Ogishima T; Shiina H; Breault JE; Terashima M; Honda S; Enokida H; Urakami S; Tokizane T; Kawakami T; Ribeiro-Filho LA; Fujime M; Kane CJ; Carroll PR; Igawa M; Dahiya R
Oncogene; 2005 Oct; 24(45):6765-72. PubMed ID: 16007175
[TBL] [Abstract][Full Text] [Related]
3. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
4. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
Tokizane T; Shiina H; Igawa M; Enokida H; Urakami S; Kawakami T; Ogishima T; Okino ST; Li LC; Tanaka Y; Nonomura N; Okuyama A; Dahiya R
Clin Cancer Res; 2005 Aug; 11(16):5793-801. PubMed ID: 16115918
[TBL] [Abstract][Full Text] [Related]
6. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
[TBL] [Abstract][Full Text] [Related]
7. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
Liu W; Gong J; Hu J; Hu T; Sun Y; Du J; Sun C; Guan M; Jiang H; Lu Y
Urology; 2011 Apr; 77(4):1006.e1-7. PubMed ID: 21310466
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
11. Heparanase expression is associated with histone modifications in glioblastoma.
Hong X; Nelson K; Lemke N; Kalkanis SN
Int J Oncol; 2012 Feb; 40(2):494-500. PubMed ID: 22001963
[TBL] [Abstract][Full Text] [Related]
12. Role of promoter methylation in regulation of the mammalian heparanase gene.
Shteper PJ; Zcharia E; Ashhab Y; Peretz T; Vlodavsky I; Ben-Yehuda D
Oncogene; 2003 Oct; 22(49):7737-49. PubMed ID: 14586400
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
14. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells.
Singal R; van Wert J; Bashambu M
Cancer Res; 2001 Jun; 61(12):4820-6. PubMed ID: 11406558
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase and DNA methyltransferase in human prostate cancer.
Patra SK; Patra A; Dahiya R
Biochem Biophys Res Commun; 2001 Sep; 287(3):705-13. PubMed ID: 11563853
[TBL] [Abstract][Full Text] [Related]
16. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
17. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Vanaja DK; Ballman KV; Morlan BW; Cheville JC; Neumann RM; Lieber MM; Tindall DJ; Young CY
Clin Cancer Res; 2006 Feb; 12(4):1128-36. PubMed ID: 16489065
[TBL] [Abstract][Full Text] [Related]
18. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
[TBL] [Abstract][Full Text] [Related]
20. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
Nojima D; Li LC; Dharia A; Perinchery G; Ribeiro-Filho L; Yen TS; Dahiya R
Cancer; 2001 Oct; 92(8):2076-83. PubMed ID: 11596023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
